BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231030
DTEND;VALUE=DATE:20231102
DTSTAMP:20260516T073402
CREATED:20230803T103923Z
LAST-MODIFIED:20230803T103923Z
UID:37564-1698624000-1698883199@www.pharmajournalist.com
SUMMARY:CRISPR-Based Therapy Analytical Development Summit
DESCRIPTION:CRISPR-based therapies are undergoing a remarkable evolution\, with drug developers striving to enhance the safety\, precision and efficacy of their products. As this paradigm takes place\, more complex CRISPR structures necessitate cutting-edge advancements in analytical methods and tools to effectively characterize the genome-edited products utilizing CRISPR technology. \nAs industry experts tread unchartered territory\, the inaugural CRISPR-Based Therapy Analytical Development Summit has been convened\, gathering more than 60 distinguished experts in analytical development devoted to the creation\, refinements and implementation of more robust analytical tools specifically tailored to CRISPR-based constructs. \nWithin this intimate space\, we will adopt a shared consensus and delve into a comprehensive array of analytical techniques central to any CRISPR-based toolkit. Topics of discussion will span pioneering technology that includes everything from novel methods to characterize the guide RNA and whole CRISPR complex\, to the use of next-generation sequencing (NGS) to detect and assess off-targets for superior safety evaluations. \nIn response to the regulatory bodies’ insistence on high-quality data to substantiate the safety and efficacy of genome-edited products\, this summit is imperative to all individual engaged in the development of analytical tools and methodologies utilizing CRISPR technology as we build for better guidance around CRISPR-edited products. \nIf your role centers around analytical expertise and gene edited specialization\, this meeting will enable you to streamline your analytical development process and connect in a shared goal to deliver safer therapies\, with superior therapeutic benefit to patients faster. \nTo know more visit: https://ter.li/28jg6x
URL:https://www.pharmajournalist.com/event/crispr-based-therapy-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR